Develops genetically engineered T cells for cancer and autoimmune diseases.
Dec 2025Revenue $0.00/yrExpenses $209M/yr
No trendCash runway ≈ 3.2 years from Jun 2026
Figures by year
When will Allogene Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $209M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $209M | −$209M |
| Dec 2024 | $22.0K | $273M | −$273M |
| Dec 2023 | $95.0K | $328M | −$328M |
| Dec 2022 | $156K | $336M | −$336M |
| Dec 2021 | $114M | $294M | −$180M |
| Dec 2020 | $0.00 | $258M | −$258M |
| Dec 2019 | $0.00 | $202M | −$202M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.